Edge Wealth Management LLC Buys 14,622 Shares of SPDR S&P Biotech ETF (XBI)

Edge Wealth Management LLC boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 6,646.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 14,842 shares of the exchange traded fund’s stock after buying an additional 14,622 shares during the period. Edge Wealth Management LLC’s holdings in SPDR S&P Biotech ETF were worth $1,065,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. United Capital Management of KS Inc. grew its position in SPDR S&P Biotech ETF by 1.7% in the 4th quarter. United Capital Management of KS Inc. now owns 14,050 shares of the exchange traded fund’s stock valued at $1,008,000 after acquiring an additional 239 shares during the last quarter. WealthPLAN Partners LLC grew its position in SPDR S&P Biotech ETF by 2.5% in the 3rd quarter. WealthPLAN Partners LLC now owns 12,345 shares of the exchange traded fund’s stock valued at $944,000 after acquiring an additional 296 shares during the last quarter. Csenge Advisory Group grew its position in SPDR S&P Biotech ETF by 2.0% in the 3rd quarter. Csenge Advisory Group now owns 17,018 shares of the exchange traded fund’s stock valued at $1,275,000 after acquiring an additional 329 shares during the last quarter. Rehmann Capital Advisory Group grew its position in SPDR S&P Biotech ETF by 33.0% in the 3rd quarter. Rehmann Capital Advisory Group now owns 1,435 shares of the exchange traded fund’s stock valued at $138,000 after acquiring an additional 356 shares during the last quarter. Finally, Palo Capital Inc. grew its position in SPDR S&P Biotech ETF by 1.4% in the 3rd quarter. Palo Capital Inc. now owns 43,522 shares of the exchange traded fund’s stock valued at $4,172,000 after acquiring an additional 602 shares during the last quarter.

SPDR S&P Biotech ETF stock traded down $0.16 during mid-day trading on Friday, hitting $82.00. The company’s stock had a trading volume of 581,594 shares, compared to its average volume of 6,872,455. SPDR S&P Biotech ETF has a one year low of $64.38 and a one year high of $101.55.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 27th. Stockholders of record on Monday, December 24th were given a dividend of $0.012 per share. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.06%. The ex-dividend date was Friday, December 21st.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/2019/01/11/edge-wealth-management-llc-buys-14622-shares-of-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Ex-Dividend

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply